Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Matsumoto (Tokyo, Japan). The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis. 4885

Member's Comments

No comment yet.

Related content which might interest you: Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020 Year: 2020 Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Fenspiride as complementary anti-inflammatory agent in therapy of patients with chronic obstructive pulmonary disease Source: Annual Congress 2011 - COPD management Year: 2011 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017 Year: 2017 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The potential impact of azithromycin in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018 Year: 2019 Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis Source: Eur Respir J, 49 (5) 1601339; 10.1183/13993003.01339-2016 Year: 2017 Acute exacerbation of idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 792 Year: 2004 The effect of long-term macrolides therapy for acute exacerbation of chronic obstructive pulmonary disease: A meta-analysis Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (2) 00036-2016; 10.1183/23120541.00036-2016 Year: 2017 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005 GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 Effect of systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 624s Year: 2006 Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1434-1445 Year: 2015 The challenge of acute exacerbation of pulmonary fibrosis Source: International Congress 2014 – PG01 Challenges faced when diagnosing idiopathic interstitial lung disease Year: 2014 Immunomodulatory efficacy of inferon in chronic obstructive pulmonary disease Source: Annual Congress 2010 - COPD: management Year: 2010